Episona has launched its male fertility test, Seed. The test is the first of its kind on the market, and measures epigenetic changes in DNA to predict the risk for male factor infertility and poor embryo development. According to the company, while male factors contribute to about half of the cases of infertility in couples, testing options for men have been lacking.
A laboratory-developed test, Seed has a turnaround time of about two weeks. Physicians receive a detailed report on patients' likelihood of contributing to infertility and poor embryo development. This information can then help both the physician and patient understand whether a couple should spend time and money pursuing less invasive procedures such as intrauterine insemination or move directly to in vitro fertilization. By detecting issues that could impact sperm’s role in embryo development, Seed results can also help identify problems that might occur with IVF and provide answers if an IVF cycle fails, the company said.